Jump to content

Potential COVID-19 vaccine from China shows promise in animal tests


snoop1130

Recommended Posts

Potential COVID-19 vaccine from China shows promise in animal tests

 

2020-06-10T084523Z_1_LYNXMPEG590NW_RTROPTP_4_HEALTH-CORONAVIRUS-ASTRAZENECA.JPG

FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration taken taken April 10, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

 

BEIJING (Reuters) - A potential COVID-19 vaccine being developed by Chinese researchers showed promise in trials in monkeys, triggering antibodies and raising no safety issues, researchers said, and a human trial with more than 1,000 participants is under way.

 

The vaccine candidate, called BBIBP-CorV, induced high-level neutralising antibodies that can block the virus from infecting cells in monkeys, rats, guinea pigs and rabbits, researchers said in a paper published in online by the medical journal Cell on Saturday.

 

"These results support the further evaluation of BBIBP-CorV in a clinical trial," researchers said in the paper. 

 

BBIBP-CorV, developed by Beijing Institute of Biological Products affiliated to state-owned China National Pharmaceutical Group (Sinopharm), is among five candidates China is testing in humans.

 

More than 100 potential COVID-19 vaccines are in various stages of development around the world. Among front runners currently in human trials are being developed by AstraZeneca, Pfizer, BioNtech, Johnson & Johnson, Merck, Moderna, Sanofi and China's CanSino Biologics.

 

As well as appearing safe and able to generate an immune response in animals, BBIBP-CorV did not appear to trigger antibodies that could boost the infection - a phenomenon known as antibody-dependent enhancement (ADE)- the researchers said, although this does not necessarily guarantee ADE won't occur in human tests.

 

Apart from BBIBP-CorV, Sinopharm, which has invested 1 billion yuan ($141.40 million) in vaccine projects, is testing in humans another vaccine candidate developed by its Wuhan-based unit. The two shots have been given to more than 2,000 people in clinical trials.

 

reuters_logo.jpg

-- © Copyright Reuters 2020-06-10
 
Link to comment
Share on other sites

6 minutes ago, snoop1130 said:

The vaccine candidate, called BBIBP-CorV, induced high-level neutralising antibodies that can block the virus from infecting cells in monkeys, rats, guinea pigs and rabbits, researchers said in a paper published in online by the medical journal Cell on Saturday.

in other words, in all 1.4 billion of them (Chinese), good luck then

  • Like 1
Link to comment
Share on other sites

When is a copy not a copy but considered an original, well that would only be when there is a power of attorney and all documents that are copies are certified as copies of an original.  So if you took a Longines watch and it was an exact duplicate with all the same parts would it be real or fake.

Link to comment
Share on other sites

125 vaccines under development at last count. 10 of these already in clinical trials with humans. One, Oxford Univ with Astro Zenica, already in Phase III.

 

Given the sheer volume of vaccine that will be needed, and needed fast,  the more manufacturers the better.

 

Good overview here

 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31252-6/fulltext

  • Like 1
Link to comment
Share on other sites

On 6/10/2020 at 12:08 PM, from the home of CC said:

if they're the first and come up with one that works and can produce it sufficient quantities they'll have the world by the cojones.. 

Its probably easier to come up with a fix for something that you made yourself in the first place

  • Haha 1
Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.







×
×
  • Create New...